



ORIGINAL

## Relationship between *algD* gene and biofilm density in clinical isolates of *Pseudomonas Aeruginosa*

## Relación entre el gen *algD* y la densidad de biopelícula en aislamientos clínicos de *Pseudomonas Aeruginosa*

Desi Wulandari<sup>1</sup> , Puspa Wardhani<sup>2</sup>  , Aryati<sup>1</sup> 

<sup>1</sup>Master of Basic Medical Sciences Student, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.

<sup>2</sup>Department of Clinical Pathology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.

Cite as: Wulandari D, Wardhani P, Aryati A. Relationship between *algD* gene and biofilm density in clinical isolates of *Pseudomonas Aeruginosa*. Salud, Ciencia y Tecnología. 2025; 5:1370. <https://doi.org/10.56294/saludcyt20251370>

Submitted: 18-06-2024

Revised: 06-10-2024

Accepted: 10-02-2025

Published: 11-02-2025

Editor: Prof. Dr. William Castillo-González 

Corresponding author: Puspa Wardhani 

### ABSTRACT

**Introduction:** infection due to *Pseudomonas aeruginosa* is a cause of nosocomial infections that are acquired when patients are hospitalized. The incidence of bacterial infections is 80 % related to biofilm formation, which is the main mediator of infection. *Pseudomonas aeruginosa* genetically produces at least three polysaccharides that help the biofilm formation process and maintain the stability of the biofilm structure, one of which is the *algD* gene.

**Objective:** analyze the relationship between the presence of the *algD* gene and biofilm density in clinical isolates of *Pseudomonas aeruginosa*.

**Method:** analytical observational research, consecutive sampling technique with a total sample of 33 clinical isolates of *Pseudomonas aeruginosa*. The biofilm formation test uses the microtiter plate assay method to determine the presence of the *algD* gene in the conventional PCR method.

**Results:** the results of the biofilm development process showed that 4 isolates (12,1 %) did not produce biofilm and 29 isolates (87,9 %) produced biofilm, including 10 isolates (30,3 %) produced weak biofilm, 13 isolates (39,4 %) produces moderate biofilm. And 6 isolates (18,2 %) produced strong biofilms. Based on PCR amplification, 31 isolates (93,9) carried the *algD* gene and 2 isolates (6,1 %) did not carry the *algD* gene. The statistical analysis results using the chi-square test obtained a p-value = 0,011.

**Conclusion:** There is a significant relationship between the presence of the *algD* gene and biofilm density in clinical isolates of *Pseudomonas aeruginosa*.

**Keywords:** *Pseudomonas Aeruginosa*; Biofilm Density; *algD* Gene.

### RESUMEN

**Introducción:** la infección por *Pseudomonas aeruginosa* es una causa de infecciones nosocomiales que se adquieren durante la hospitalización de los pacientes. La incidencia de infecciones bacterianas está relacionada en un 80 % con la formación de biopelículas, que es el principal mediador de la infección. *Pseudomonas aeruginosa* produce genéticamente al menos tres polisacáridos que ayudan en el proceso de formación de biopelículas y mantienen la estabilidad de la estructura de la biopelícula, uno de los cuales es el gen *algD*.

**Objetivo:** analizar la relación entre la presencia del gen *algD* y la densidad de biopelículas en aislados clínicos de *Pseudomonas aeruginosa*.

**Método:** estudio observacional analítico mediante técnica de muestreo consecutivo con una muestra total de 33 aislados clínicos de *Pseudomonas aeruginosa*. La prueba de formación de biopelículas utiliza el método

de ensayo en placa de microtitulación y para determinar la presencia del gen *algD* utiliza el método de PCR convencional.

**Resultados:** los resultados del proceso de desarrollo de biopelículas mostraron que 4 aislados (12,1 %) no produjeron biopelícula y 29 aislamientos (87,9 %) produjeron biopelícula, de los cuales 10 aislados (30,3 %) produjeron biopelícula débil, 13 aislados (39,4 %) producen biopelícula moderada. biopelícula. biopelícula y 6 aislados (18,2 %) produjeron biopelículas fuertes. Según la amplificación por PCR, 31 aislados (93,9) portaban el gen *algD* y 2 aislados (6,1 %) no portaban el gen *algD*. Los resultados del análisis estadístico mediante la prueba de chi-cuadrado obtuvieron valor de  $p = 0,011$ .

**Conclusión:** existe una relación significativa entre la presencia del gen *algD* y la densidad de biopelículas en aislados clínicos de *Pseudomonas aeruginosa*.

**Palabras clave:** *Pseudomonas Aeruginosa*; Densidad de Biopelícula; Gen *algD*.

## INTRODUCTION

Humans are susceptible to opportunistic infections caused by *Pseudomonas aeruginosa*. is a Gram-negative bacterium, invasive and toxogenic, can cause infections, and is the cause of nosocomial infections acquired when hospitalized.<sup>(1)</sup> The incidence of infection due to *Pseudomonas aeruginosa* in Indonesia reaches around 30 %.<sup>(2)</sup> Studies conducted in 11 DKI Jakarta hospitals revealed that 9,8 % of inpatients experienced nosocomial infections.<sup>(3)</sup> Nosocomial infections usually occur in patients with pus wound infections, burns, cystic fibrosis, and septicemia.<sup>(4)</sup> *Pseudomonas aeruginosa* pathogenesis is dependent on virulence factors, which are essential for both host tissue invasion and bacterial colonization, both of which can exacerbate infections. Biofilm is one of *Pseudomonas aeruginosa*'s key virulence factors.<sup>(5)</sup>

Biofilm is a collection of bacteria that have attached to tissue and are coated with extracellular matrix and polysaccharides produced by the bacteria themselves. This makes the bacteria resistant to antibiotics and makes treating infections more difficult.<sup>(6)</sup> The incidence of bacterial infections is approximately 80 % associated with the formation of biofilms, making biofilms the main mediator causing infection.<sup>(7)</sup> Matrix components in biofilm formation include nucleic acids, lipids, polysaccharides, and proteins.<sup>(8)</sup> The stability of the biofilm structure depends on the genetic production of at least three polysaccharides by *Pseudomonas aeruginosa*: alginate, pel, and psl.<sup>(9)</sup> The Alginate gene is a polysaccharide that is produced in response to stress linked to chronic infection, whereas the Psl and Pel genes are crucial for the early phases of biofilm formation, namely during the acute phase of infection.<sup>(10)</sup> Only non-mucoid bacteria can create pel and PSL, although mucoid bacteria can produce alginate.

Alginate's advantages are that it protects against biofilm architecture and facilitates the colonization process. Overproduction of alginate boosts the biofilm-forming capability and increases the pathogenicity of *Pseudomonas aeruginosa*.<sup>(11,12)</sup>  $\alpha$ -L-guluronic acid and  $\beta$ -D-mannuronic acid make up the polymer alginate. It contributes to both biofilm stability and cell defense and is crucial for the biofilm's ability to retain water and nutrients.<sup>(13)</sup> *AlgD* is the first gene involved in alginate manufacture, and most alginate-producing genes are found in vast operons. *algD* transcriptional activation is a key point in regulating the alginate synthesis pathway.<sup>(14)</sup> The *algD* gene has an important role for *Pseudomonas aeruginosa* bacteria, namely encoding GDP mannose dehydrogenase, an important enzyme of the Alginate and polymer biosynthetic pathway that represents an important protection mechanism for bacteria. The *algD* gene is essential in biofilm structuring and regulates Alginate capsule polysaccharides and virulence factors.<sup>(15)</sup>

Biofilm density refers to the total number of bacterial cells trapped in the matrix that forms the biofilm and will form a density. The biofilm is at the edge of the dissolved microtiter plate. The microtiter plate is a quantitative method that is the gold standard for testing Bacteria that have the ability to stick to the plastic surface of the microtiter plate. The advantages of using the microtiter plate method are the ease of use of basic laboratory materials and adaptation to small or large samples that can be tested in a single measurement.<sup>(16)</sup> The disadvantage of using this method is the use of crystal violet dye which raises concerns due to its environmental toxicity.<sup>(17)</sup>

The testing method for detecting the *algD* gene in *Pseudomonas aeruginosa* is Polymerase Chain Reaction (PCR). PCR is an enzymatic method for amplifying DNA in vitro, Has advantages in terms of speed, specificity, and sensitivity in detecting a microorganism, making PCR the "method of choice".<sup>(18)</sup> The disadvantage of the PCR method is the possibility of false positives or negatives. The limitation of PCR is that it requires special equipment and is not cheap.<sup>(19)</sup> Previous research focused on the presence or absence of genes in biofilm producing bacteria. Research on the relationship between the *algD* gene and biofilm density in clinical isolates of *Pseudomonas aeruginosa* is very rarely carried out in Indonesia, especially in Surabaya. The research aims to determine the ability of various clinical isolates of *Pseudomonas aeruginosa* to produce biofilms and their relationship with the *algD* gene.

## METHOD

This study design used observational analysis using clinical isolates of *Pseudomonas aeruginosa* in the Clinical Microbiology Unit of Airlangga University Hospital, Surabaya. This study received approval from the Health Research Ethics Committee at Airlangga University Hospital. Through a letter with the number: 097/KEP/2024.

### Sample

Clinical isolates that have been identified as *Pseudomonas aeruginosa* with a sample probability percentage of  $\geq 93\%$  using the VITEK 2 Compact tool were collected and stored in cryotubes containing TSB liquid media and 20 % glycerol, then stored in a freezer at a temperature of  $-80^{\circ}\text{C}$  in the Clinical Microbiology Unit of Airlangga University Hospital. The sample collection process was carried out in July 2024 - September 2024. The collected samples were continued with biofilm density examination using an ELISA Reader (BioRad iMark Microplate Reader) and detection of the *algD* gene with PCR (SimpliAmp™ Thermal Cycler) carried out at the Dengue Institute of Tropical Disease (ITD) Laboratory, Airlangga University. We used *Pseudomonas aeruginosa* PAO1 as a positive control for the examination of the *algD* gene and biofilm density.

### Preparation of Microbial Samples

Samples of clinical isolates of *Pseudomonas aeruginosa* obtained from the Clinical Microbiology of Airlangga University Hospital were inserted into a cryotube containing Tryptic Soy Broth (TSB) medium and 20 % glycerol which was stored at a temperature of  $37^{\circ}\text{C}$  for 24 hours and then stored in a freezer of  $-80^{\circ}\text{C}$ . Bacterial isolates in Tryptic Soy Broth (TSB) medium and 20 % glycerol were taken using a sterile ose needle inserted into MacConkey agar media for bacterial growth and kept in an incubator for 24 hours at  $37^{\circ}\text{C}$ . Bacterial isolates grown in MacConkey agar media were then subcultured on MacConkey agar media and thereafter incubated for 24 hours at  $37^{\circ}\text{C}$ .

### Biofilm Assay

After subculture for 48 hours, bacterial colonies were taken using sterile cotton swabs and then inserted into a test tube containing 0,45 % NaCl solution as a standard McFarland 0,5 solution. The tube containing 1,980  $\mu\text{l}$  of Tryptic Soy Broth (TSB) was added with 20  $\mu\text{l}$  of *Pseudomonas aeruginosa* bacterial suspension, then inserted into each well of the microtiter plate as much as 200  $\mu\text{l}$ . The microtiter plate was closed and incubated at  $37^{\circ}\text{C}$  for 24 hours. The wells were washed using Phosphate Buffer Saline (pH 7,2) three times and then dried by turning them upside down to dry in the open air. The bacterial biofilm bound to the well was fixed with 150  $\mu\text{l}$  of 96 % methanol for 20 minutes. The microtiter plate was tapped at each washing process to remove the solution from the well. Biofilm with 1 % Crystal violet for 5 minutes and rinse gently 3 times with distilled water. Biofilm attached to the walls and bottom of the tube that has been stained with crystal violet will be dissolved with 150  $\mu\text{l}$  of 96 % ethanol in each well. The preparation was left at room temperature for 5 minutes. The thickness of the biofilm attached to the bottom of the microtiter plate well was read using an ELISA reader with an Optical Density value read at  $\lambda$  595 nm. This examination was repeated 3 times. The optical density value of each isolate ( $\text{ODi}$ ) was taken and averaged over the triple wells, then the results were compared with the negative control optical density ( $\text{ODc}$ ). Isolates were categorized into four categories, based on the average optical density (OD) associated with the  $\text{ODc}$  values. The four Categories are based as follows:  $\text{ODi} \leq \text{ODc}$  indicates non-compliance;  $\text{ODc} < \text{ODi} \leq 2 \times \text{ODc}$  indicates weak compliance (+);  $2 \times \text{ODc} < \text{ODi} \leq 4 \times \text{ODc}$  indicates moderate compliance (++); and  $4 \times \text{ODc} < \text{ODi}$  indicates very compliant (+++). As a negative control, TSB broth devoid of bacterial inoculum was employed. <sup>(27)</sup>

### *algD* Gene Detection

#### DNA Extraction

DNA was extracted using the Biospin Bacteria Genomic DNA Extraction Kit (BIOER, China) depending on the DNA extraction procedure. To be used in PCR, the isolated DNA was kept at  $-20^{\circ}\text{C}$ . Primary: In this study, specific primers of the *algD* gene were designed based on the NCBI gene sequence information base. The primers were prepared by Costum oligo Macrogen, South Korea, as shown in (table 1).

Table 1. <i>algD</i> gene primers (July 07, 2024, Surabaya)			
Gene	Primary	Primary Sequence (5'-3')	Amplicon size (bp)
<i>algD</i>	F	AGAAGTCCGAACGCCACACC	550bp
	R	CGCATCAACGAACCGAGCATC	

The reagent used is Master mix (NEXpro™ e PCR 2X Master Mix), Composition of materials examined in PCR: Master mix as much as 12,5  $\mu\text{l}$ , 1  $\mu\text{l}$  primer forward gene *algD*, 1  $\mu\text{l}$  primer reverse gene *algD*, 7,5  $\mu\text{l}$  ddH<sub>2</sub>O. The

total final volume is 20 µl/sample tube. DNA template (sample) is pipetted as much as 3 µl which has been filled with 20 µl PCR mix so that the total final volume of each tube is 25 µl. PCR amplification with PCR SimpliAmp™ Thermal Cycler with PCR program settings, namely, predenaturation 95 °C 5 minutes, denaturation 95 °C 2 minutes, annealing 63°C 30 seconds, extension 72 °C 1 minute, the number of cycles is 35 times. Final Extension 72 °C 5 minutes. The PCR results were then electrophoresed on a 2 % agarose gel for 30 minutes at 100 Volts and visualized using a UV transilluminator. Positive PCR results of the *algD* gene and positive control (*Pseudomonas aeruginosa* PAO1) were indicated by the appearance of DNA fragments of 550 bp each.<sup>(11)</sup>

### Statistical Methods

Statistical data analysis was conducted by correlation analysis using Fisher's Exact Test to examine the association between the *algD* gene and biofilm density in clinical isolates of *Pseudomonas aeruginosa* using the SPSS version 25 software. Fisher's exact test was employed with a p-value of 0,05 to assess significance.

## RESULTS

### Distribution of Specimens in Clinical Isolates of *Pseudomonas aeruginosa*

During the research period from July to November 2024, 33 clinical isolates of *Pseudomonas aeruginosa* were obtained from patients at Airlangga University Hospital. Of these, the largest number of isolates came from sputum specimens with 22 isolates (66,67 %), followed by urine specimens with 6 isolates (18,18 %). In addition, 3 isolates (9,09 %) came from pus specimens, and 2 isolates (6,06 %) were obtained from blood specimens. Data on the distribution and characteristics of these isolates are based on the recording of *Pseudomonas aeruginosa* culture examination logbooks conducted in the Clinical Microbiology Laboratory of Airlangga University Hospital.

**Table 2.** Distribution of *Pseudomonas aeruginosa* Clinical Isolate Specimens (September 09, 2024, Surabaya)

Specimen	Number of Specimens	Percentage
Sputum	22	66,67 %
Urine	6	18,18 %
Blood	3	9,09 %
Pussy	2	6,06 %
Total	33	100 %

### Biofilm Density Examination Results on Clinical Isolates of *Pseudomonas aeruginosa*

**Table 3.** Biofilm Density of Clinical Isolates of *Pseudomonas aeruginosa* (September 09, 2024, Surabaya)

Biofilm Density	Number of Isolates	Isolate percentage
Does Not Produce Biofilm (-)	4	12,1 %
Producing Weak Biofilm (+)	10	30,3 %
Producing Moderate Biofilm (++)	13	39,4 %
Producing Strong Biofilm (+++)	6	18,2 %
Total	33	100 %

### Results of *algD* gene examination in clinical isolates of *Pseudomonas aeruginosa*

**Table 4.** The *algD* gene in clinical isolates of *Pseudomonas aeruginosa* (Airlangga University Hospital, Surabaya, 2024)

Number of <i>Pseudomonas aeruginosa</i> Isolates	<i>algD</i> gene (+)	<i>algD</i> gene (-)
33	31(93,9 %)	2 (6,1 %)




Figure 1. Elektroforesis gel agarosa (gen *algD* produk PCR, the band 550 bp) (Airlangga University Hospital, Surabaya, 2024)

Table 5. Relationship between *algD* gene and biofilm density in clinical isolates of *Pseudomonas aeruginosa* (Airlangga University Hospital, Surabaya, 2024)

Biofilm Density	<i>algD</i> gene (+)	<i>algD</i> gene (-)
Does Not Produce Biofilm	2 (50 %)	2 (50 %)
Producing Weak Biofilms	10 (100 %)	0 (0 %)
Producing Medium Biofilms	13 (100 %)	0 (0 %)
Producing Strong Biofilms	6 (100 %)	0 (0 %)
Total	31	2

A significant association (p-value of 0,011) was found between biofilm density and the presence of the *algD* gene in clinical isolates of *pseudomonas aeruginosa*, according to statistical data analysis using Fisher's exact test.

## DISCUSSION

The distribution of clinical isolate specimens of *Pseudomonas aeruginosa* in this study showed a dominant pattern in the type of sputum specimen, namely 22 (66,67 %). This reflects that *Pseudomonas aeruginosa* is more often found in respiratory tract infections, where patients who have respiratory diseases can reduce their respiratory immunity and make them susceptible to *Pseudomonas aeruginosa* infection.<sup>(20)</sup> The percentage of isolates from urine specimens (18,18 %), supports the fact that this bacteria is often involved in urinary tract infections related to catheterization during surgical procedures in hospitals or in other urinary tract diseases that facilitate the colonization of *Pseudomonas aeruginosa* bacteria.<sup>(21)</sup> Pus isolates (9,09 %) indicate wound infection and blood (6,06 %) indicate bloodstream infection.

In this study, the ability to form biofilms in clinical isolates of *Pseudomonas aeruginosa* in 33 isolates obtained results, namely 4 (12,1 %) did not produce biofilms and 29 (87,9 %) were able to produce biofilms, including 10 (30,3 %) producing weak biofilms, 13 (39,4 %) producing moderate biofilms and 6 (12,1 %) producing strong biofilms.

Research conducted by Vasiljevic et al. involving 163 *Pseudomonas aeruginosa* isolates revealed that 97,55 % of these isolates were capable of producing biofilm. Among them, 39,26 % formed strong biofilms, 34,36 % medium biofilms, 23,93 % weak biofilms and 2,45 % of the isolates did not produce biofilms. According to Banar et al., Isolates that developed biofilms generated 21,8 % weak, 47,3 % medium, and 30,9 % robust biofilms. 2 isolates, representing 3,5 % did not produce any biofilm at all.<sup>(22)</sup>

The biofilm formed protects bacteria from the body's immune system and antibiotic therapy, resulting in infections that are difficult to treat and require longer treatment times. The spread of isolates that can produce biofilms is a problem for public health because it has the potential to increase morbidity rates, mortality, and



antimicrobial resistance, especially in immunocompetent patients.<sup>(23)</sup>

In this study, the results of PCR amplification showed that the *algD* gene was detected in as many as 31 (93,9 %) of 33 clinical isolates of *Pseudomonas aeruginosa*. This outcome is consistent with a research by Banar et al. that found that 100 % of the 57 isolates of *Pseudomonas aeruginosa* had the *algD* gene. In addition, another study conducted reported *algD* gene frequencies of 98 %, 87,5 %, and 78,9 %, respectively.<sup>(11,14,23)</sup>

The findings of the study demonstrated a significant relationship ( $p = 0,011$ ) between the biofilm density and the presence of the *algD* gene in clinical isolates of *Pseudomonas aeruginosa*. The research results are in line with Rajabi et al, who identified a significant association between the presence of the *algD* gene and the development of biofilms in *Pseudomonas aeruginosa* clinical isolates, with a  $p$ -value greater than 0,01.

*Pseudomonas aeruginosa* strains carrying biofilm-forming genes, such as *algD*, are known to have a higher capacity to cause severe infections.<sup>(24)</sup> The resulting biofilm protects the germs from the body's immune system and antibiotic therapy, resulting in infections that are difficult to treat and require a longer treatment time.<sup>(25)</sup>

The *algD* gene encodes the enzyme GDP-mannose dehydrogenase, a key step in alginate biosynthesis. The primary precursor for alginate production, GDP-mannose, is changed by this enzyme into GDP-mannuronate. Alginate is crucial for protecting biofilms and giving them structural stability. Alginate is the main exopolysaccharide in the biofilm matrix that protects against antibiotics and the immune system.<sup>(26)</sup> Consistent detection of the *algD* gene in most isolates indicates the importance of the *algD* gene to the virulence of *Pseudomonas aeruginosa*. High detection of the *algD* gene suggests that this gene is a relevant molecular target for the diagnosis or development of therapies aimed at inhibiting biofilm formation.

The spread of isolates with biofilm-forming ability is a serious challenge for public health because can potentially increase morbidity, mortality, and antimicrobial resistance. These results emphasize the importance of monitoring biofilm-forming genes in *Pseudomonas aeruginosa* isolates as a step to identify the risk of wider spread of infection and design strategies for more effective infection control. A limitation of the study was not testing Alginate levels produced by mucoid and non-mucoid strains so it could not verify whether the presence of the *algD* gene was directly correlated with Alginate production. The study did not test other genes (*Psl* and *Pel*) to determine the influence of other genes on biofilm formation.

## CONCLUSION

According to the study, biofilm density and the presence of the *algD* gene in clinical isolates of *Pseudomonas aeruginosa* were significantly correlated.

## REFERENCES

1. Turkina MV & Vikström E. Bacteria-Host Crosstalk: Sensing of the Quorum in the Context of *Pseudomonas aeruginosa* Infections. *J of Innate Immunity*. 2019;11(3):263-279. Available from: <https://doi.org/10.1159/000494069>
2. Radji M. Microbiology Textbook Guide for Pharmacy and Medical Students (J. Manurung, Ed.). 2011. EGC Medical Book Publisher.
3. Suarmayasa NI. Germ Patterns on Sphygmomanometer Cuffs: A Descriptive Study at Mangusada Hospital. *National Health Research Journal*. 2023;7(2):163-168. <https://doi.org/10.37294/jrkn.v7i2.481>
4. Gunawan K, Farrasizdihar D, Prosperita T, Wau K, Ziraluo EC, Eliza Y & Lubis P. Antibacterial Effectiveness Test of Persimmon Fruit Extract (*Diospyros Kaki*) Against the Growth of *Pseudomonas Aeruginosa* Bacteria. 2019;166-169. Available from: <https://seminar-id.com/semnas-sainteks2019.html>
5. Rajkowska K, Otlewska A, Guiamet PS, Wrzosek H & Machnowski W. Pre-columbian archeological textiles: A source of *Pseudomonas aeruginosa* with virulence attributes. *Applied Sciences (Switzerland)*. 2020;10(1). Available from: <https://doi.org/10.3390/app10010116>
6. Worthington RJ, Richards JJ & Melander C. Small molecule control of bacterial biofilms. *Organic & Biomolecular Chemistry*. 2012;10(37): 7457. Available from: <https://doi.org/10.1039/c2ob25835h>
7. Vetrivel A, Ramasamy M, Vetrivel P, Natchimuthu S, Arunachalam S, Kim GS & Murugesan R. *Pseudomonas aeruginosa* Biofilm Formation and Its Control. *Biologics*. 2021;1(3):312-336. Available from: <https://doi.org/10.3390/biologics1030019>
8. Franklin MJ, Nivens DE, Weadge JT & Howell PL. Biosynthesis of the *Pseudomonas aeruginosa* Extracellular Polysaccharides, Alginate, *Pel*, and *Psl*. *Frontiers in Microbiology*. 2011;2. Available from: <https://doi.org/10.3389/fmicb.2011.00001>

org/10.3389/fmicb.2011.00167

9. Balducci E, Papi F, Capialbi DE & Del Bino L. Polysaccharides' Structures and Functions in Biofilm Architecture of Antimicrobial-Resistant (AMR) Pathogens. *International Journal of Molecular Sciences*. 2023;24(4):4030. Available from: <https://doi.org/10.3390/ijms24044030>

10. Ghadaksaz A, Fooladi AAI, Mahmoodzadeh HH & Amin M. The prevalence of some *Pseudomonas* virulence genes related to biofilm formation and alginate production among clinical isolates. *J of Applied Biomedicine*. 2015;13(1):61-68. Available from: <https://doi.org/10.1016/j.jab.2014.05.002>

11. Heredia PZ, de Vicente A, Cazorla FM & Gutiérrez BJA. Beyond the Wall: Exopolysaccharides in the Biofilm Lifestyle of Pathogenic and Beneficial Plant-Associated *Pseudomonas*. *Microorganisms*. 2021;9(2):445. Available from: <https://doi.org/10.3390/microorganisms9020445>

12. Wei Q & Ma L. Biofilm Matrix and Its Regulation in *Pseudomonas aeruginosa*. *International Journal of Molecular Sciences*. 2013;14(10):20983-21005. Available from: <https://doi.org/10.3390/ijms141020983>

13. Rajabi H, Salimizand H, Khodabandehloo M, Fayyazi A & Ramazanzadeh R. Prevalence of *algD*, *pslD*, *pelF*, *Ppgl*, and *PAPI-1* Genes Involved in Biofilm Formation in Clinical *Pseudomonas aeruginosa* Strains. *BioMed Research International*. 2022. Available from: <https://doi.org/10.1155/2022/1716087>

14. Al-Draghi W & Al-fridawy R. Synergistic Effect of Amikacin and Ciprofloxacin on *pelA* and *algD* Genes in *Pseudomonas aeruginosa*. *Indian Journal of Forensic Medicine & Toxicology*. 2020;14(4).

15. Coffey BM & Anderson GG. Biofilm Formation in the 96-Well Microtiter Plate. 2014;1149:631-641. Available from: [https://doi.org/10.1007/978-1-4939-0473-0\\_48](https://doi.org/10.1007/978-1-4939-0473-0_48)

16. Ommen P, Zobek N & Meyer RL. Quantification of biofilm biomass by staining: Non-toxic safranin can replace the popular crystal violet. *J of Microbiological Methods*. 2017;141: 87-89. Available from: <https://doi.org/10.1016/j.mimet.2017.08.003>

17. Fazri M, Kartika AI, Darmawati S & Ethica NS. Isolation and Identification of Molecular Bacteria *Staphylococcus epidermidis* on Rusip Tiger Prawn (*Penaeus monodon*) 24 Hour Post-Fermentation Based on Gene 16S rRNA Sequence. 2019. Available from: <http://prosiding.unimus.ac.id>

18. Yu ACH, Vatcher G, Yue X, Dong Y, Li MH, Tam, et al. Nucleic acid-based diagnostics for infectious diseases in public health affairs. *Frontiers of Medicine in China*. 2012;6(2): Available from: 173-186. <https://doi.org/10.1007/s11684-012-0195-5>

19. Wang CY, Jerng JS, Cheng KY, Lee LN, Yu CJ, Hsueh PR, et al. Pandrug-resistant *Pseudomonas aeruginosa* among hospitalized patients: clinical features, risk factors and outcomes. *Clinical Microbiology and Infection*. 2006;12(1):63-68. Available from: <https://doi.org/10.1111/j.1469-0691.2005.01305.x>

20. Mittal R, Khandwaha RK, Gupta V, Mittal PK & Harjai K. Phenotypic characteristics of urinary isolates of *Pseudomonas aeruginosa* & their association with mouse renal colonization. *Indian J Med Res*. 2006;123(1):67-72.

21. Banar M, Emameini M, Satarzadeh M, Abdellahi N, Beigverdi R, Leeuwen, et al. Evaluation of Mannosidase and Trypsin Enzymes Effects on Biofilm Production of *Pseudomonas aeruginosa* Isolated from Burn Wound Infections. *PLOS ONE*. 2016;11(10): e0164622. Available from: <https://doi.org/10.1371/journal.pone.0164622>

22. Namuq AO, Ali KOM & Al-Ani AH. Correlation between Biofilm Formation, Multi-Drug Resistance and *AlgD* Gene among *Pseudomonas aeruginosa* Clinical Isolates. *J of the University of Babylon for Pure and Applied Sciences*. 2019;27(3):143-149.

23. Johnson WM, Tyler SD, Ewan EP, Ashton FE, Pollard DR & Rozee KR. Detection of genes for enterotoxins, exfoliative toxins, and toxic shock syndrome toxin 1 in *Staphylococcus aureus* by the polymerase chain reaction. *J of Clinical Microbiology*. 1991;29(3):426-430. Available from: <https://doi.org/10.1128/jcm.29.3.426-430.1991>

24. Liu J, Chen H, Bao J, Liu S, Chen Y, Cui X, et al. Clinical Distribution and Drug Resistance of *Pseudomonas aeruginosa* in Guangzhou, China from 2017 to 2021. *J of Clinical Medicine*. 2023;12(3):1189. Available from: <https://doi.org/10.3390/jcm12031189>

25. Pedersen SS, Hoiby N, Espersen F & Koch C. Role of alginate in infection with mucoid *Pseudomonas aeruginosa* in cystic fibrosis. 1992;(47):6-13.

26. Stepanovic S, Vukovic D, Hola V, Bonaventura G, Djukic S, Ćirkovic I, et al. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. *APMIS*. 2017;115(8):891-899. Available from: [https://doi.org/10.1111/j.1600-0463.2007.apm\\_630](https://doi.org/10.1111/j.1600-0463.2007.apm_630)

#### **FINANCING**

The authors did not receive financing for the development of this research.

#### **CONFLICT OF INTEREST**

The authors declare that there is no conflict of interest.

#### **AUTHORSHIP CONTRIBUTION**

*Conceptualization:* Desi Wulandari.

*Data curation:* Desi Wulandari, Puspa Wardhani, Aryati.

*Formal analysis:* Desi Wulandari.

*Research:* Desi Wulandari.

*Methodology:* Desi Wulandari, Puspa Wardhani, Aryati.

*Project management:* Desi Wulandari, Puspa Wardhani, Aryati.

*Resources:* Desi Wulandari, Puspa Wardhani, Aryati.

*Software:* Desi Wulandari.

*Supervision:* Puspa Wardhani, Aryati.

*Validation:* Puspa Wardhani, Aryati.

*Display:* Puspa Wardhani, Aryati.

*Drafting - original draft:* Desi Wulandari.

*Writing - proofreading and editing:* Desi Wulandari, Puspa Wardhani.